SLC5A2 and type 2 diabetes mellitus: However, it remains unclear whether SGLT2 inhibitors are superior to DPP-4 inhibitors in reducing cardiovascular or cardiometabolic risk factors in patients with early-stage T2DM, without CVD, and with preserved cardiac function.